ClinicaliQ Trial Snapshot
- A Trial of Setmelanotide in Acquired Hypothalamic Obesity — Active Not Recruiting • Phase III • Diabetes / Metabolic • NCT05774756.
- Setmelanotide daily injections tested for weight loss and quality of life improvement in acquired hypothalamic obesity patients aged 4+ years.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for 52 weeks on a therapeutic regimen. A separate sub-study in patients with congenital HO is detailed under NCT06760546. Conditions: Hypothalamic Obesity Interventions: Setmelanotide, Placebo Lead Sponsor: Rhythm…